List view / Grid view
13 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Results showed that mortality was higher in patients over 70 who were either not tested with Oncotype DX or had a recurrence score result greater than 18...
11 October 2016 | By Niamh Louise Marriott, Digital Content Producer
DS-8201a is an investigational antibody drug conjugate comprised of a humanised anti-HER2 antibody attached by a peptide linker to a novel topoisomerase...
10 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The results demonstrate that LEE011 plus letrozole reduced the risk of death or progression by 44%. The combination significantly improved PFS across...
18 August 2016 | By The Institute of Cancer Research, London
In a study of nearly 2000 patients, researchers found that women whose tumours had high F12 activity and low STC2 activity had a 32% chance of dying within 10 years, whereas those with low F12 activity and high STC2 activity had only a 10% chance of dying...
13 July 2016 | By Victoria White, Digital Content Producer
Lilly and Boehringer Ingelheim are to collaborate on a Phase Ib study of abemaciclib and BI 836845 in patients with HR+, HER2- metastatic breast cancer...
20 June 2016 | By Victoria White, Digital Content Producer
Researchers have discovered that an existing medication, denosumab, may prevent breast cancer in women carrying a faulty BRCA1 gene...
27 May 2016 | By Victoria White, Digital Content Producer
The Phase III FALCON trial compared Faslodex to Arimidex for the treatment of locally-advanced or metastatic breast cancer, in post-menopausal women...
20 May 2016 | By Katie Sadler
NICE has announced it will not be recommending pertuzumab to treat HER2-positive breast cancer because it is uncertain of the long term benefits for patients.
12 May 2016 | By Victoria White, Digital Content Producer
Newly published data validate the distinct vascular remodelling activity of Halaven (eribulin) compared to bevacizumab in breast tumour tissue...
20 April 2016 | By Victoria White, Digital Content Producer
Pfizer has announced positive top-line results from the Phase III PALOMA-2 trial for Ibrance (palbociclib) in breast cancer...
11 March 2016 | By Victoria White
A trial has shown that lapatinib plus trastuzumab before surgery shrinks and may even destroy tumours in women with HER2+ breast cancer within 11 days. The EPHOS B trial studied 257 women with HER2 positive breast cancer in the short gap between initial diagnosis and surgery to remove their tumours.…
8 March 2016 | By Victoria White
The approval expands the use of Faslodex and offers additional options for US women with HR+, HER2- metastatic breast cancer…
3 March 2016 | By Victoria White
In a study, some 67% of 347 women given palbociclib plus fulvestrant showed clinical benefit compared with 40% of 174 women given placebo plus fulvestrant...
1 March 2016 | By Victoria White
The breast cancer treatment pipeline’s exceptional levels of activity and innovation may significantly alter the clinical and commercial landscape, says GBI Research...
23 February 2016 | By Victoria White
Ibrance is approved for the treatment of HR+, HER2- advanced or metastatic breast cancer in combination with fulvestrant in women with disease progression following endocrine therapy...
